CytomX Therapeutics Inc at Barclays Global Healthcare Conference Transcript
Afternoon. My name is Geoff Meacham. I'm the senior biopharma analyst here at Barclays. We are thrilled to have CytomX Therapeutics present this afternoon and speaking of -- on behalf of CytomX is Chairman and CEO, Sean McCarthy. Sean?
Great. Thank you very much, Geoff, and good afternoon, everybody. Pleasure to be here to present an update on our company.
So as you'll hear over the next 24 minutes or so, what we're doing at CytomX is really rethinking the therapeutic antibody, initially for the treatment of cancer, rethinking and, if you like, reimagining therapeutic antibodies. Over the course of the next few minutes, I will be making certain forward-looking statements. I refer you to our regulatory filings on our website.
So of course, we all know that therapeutic antibodies are a very successful antibody therapeutic class. These are powerful and potent modalities
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
